title: Drug interactions of lipid-altering drugs.
abstract: The use of lipid-altering drugs has been shown to reduce the progression of atherosclerotic lesions and reduce the risk of atherosclerotic events (such as myocardial infarction and stroke). In general, these lipid-altering drugs are well tolerated but there is the potential for drug interactions. For example, HMG-CoA reductase inhibitors may interact with macrolides, azalides, azole antifungals and cyclosporin. Resins (such as cholestyramine and colestipol) may impair the absorption of many concurrent medications. Fibrates have potential drug interactions with warfarin, furosemide (frusemide), oral hypoglycaemics and probenecid. Nicotinic acid (niacin) may have potential drug interactions with high dose aspirin (acetylsalicylic acid), uricosuric agents (such as sulfapyrazone) and alcohol (ethanol). Finally, probucol may have potential drug interactions with antidysrhythmics, tricyclic antidepressants and phenothiazines. In addition, lipid-altering drugs, used in combination, may have the potential for drug interactions, enhancing some of the risks of adverse effects, such as myositis and hepatotoxicity. Therefore, in order to use lipid-altering drugs in the most effective, and safest manner, it is important for the clinician to have an understanding of the mechanisms of potential drug interactions, which drug interactions may theoretically occur, and specifically, which spe cific drug interactions have already been described.
authors.affiliation: Louisville Metabolic and Atherosclerosis Research Center, Audubon Regional Medical Center, Kentucky, USA.
authors.forename: H E
authors.initials: HE
authors.lastname: Bays
authors.forename: C A
authors.initials: CA
authors.lastname: Dujovne
mesh_terms: D000075202:Contraindications; D004347:Drug Interactions; D011345:Fenofibrate / Q000494:pharmacology; D005395:Fish Oils / Q000494:pharmacology; D015248:Gemfibrozil / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D009525:Niacin / Q000494:pharmacology; D011341:Probucol / Q000494:pharmacology; D012116:Resins, Plant / Q000494:pharmacology
chemical_list: D005395:Fish Oils; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D012116:Resins, Plant; D009525:Niacin; D011341:Probucol; D015248:Gemfibrozil; D011345:Fenofibrate